SPN and diffuse large B-cell lymphoma: CD43+ DLBCL patients also had significantly poorer EFS (median EFS: 14 months vs 82 months, P < 0.001) and OS (median OS: 27 vs 90 months, P < 0.001) than CD43− DLBCL patients (Figure 2B,E).